Continuing patients were randomized ( 2:2:1 ratio ) to alirocumab 75 mg self-administered via single 1 mL prefilled pen every 2 weeks or ezetimibe 10 mg/day or atorvastatin 20 mg/day ( statin rechallenge ) , for 24 weeks .